Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLIGHT-FXR: Tropifexor in Patients With NASH
jRCT2080223679Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of tropifexor in metabolic dysfunction-associated steatohepatitis (MASH) (6 arms), sponsored by Novartis. Started Oct 2017; status: completed.
02
Drugs
tropifexor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2080223679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223679.